APA (7th ed.) Citation

Kontandreopoulou, C., Diamantopoulos, P. T., Giannopoulos, A., Symeonidis, A., Kotsianidis, I., Pappa, V., . . . Viniou, N. (2022). Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. Leukemia & Lymphoma, 63(3), 729. https://doi.org/10.1080/10428194.2021.1998484

Chicago Style (17th ed.) Citation

Kontandreopoulou, Christina-Nefeli, et al. "Bone Marrow Ribonucleotide Reductase MRNA Levels and Methylation Status as Prognostic Factors in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine." Leukemia & Lymphoma 63, no. 3 (2022): 729. https://doi.org/10.1080/10428194.2021.1998484.

MLA (9th ed.) Citation

Kontandreopoulou, Christina-Nefeli, et al. "Bone Marrow Ribonucleotide Reductase MRNA Levels and Methylation Status as Prognostic Factors in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine." Leukemia & Lymphoma, vol. 63, no. 3, 2022, p. 729, https://doi.org/10.1080/10428194.2021.1998484.